Deal overview
| Target | QIAGEN NV |
|---|---|
| Bidder | THERMO FISHER SCIENTIFIC INC |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | Mar 03, 2020 |
| Abstract | On 3 March 2020, the quoted US-based life sciences company Thermo Fisher Scientific Inc ("Thermo Fisher") announced a recommended cash offer for QIAGEN NV ("QIAGEN"), a Dutch diagnostics company listed in Frankfurt and New York. The offer of €39 per share valued 100% of QIAGEN's equity at approximately €9.2 billion. The transaction, which was expected to be completed in ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
